The Aurum Institute: Tembisa Clinical Research Centre
Welcome,         Profile    Billing    Logout  
 17 Trials 
21 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Churchyard, Gavin
NCT05118490: Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Recruiting
4
1000
RoW
Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks
The Aurum Institute NPC, Johns Hopkins University
HIV Seropositivity, Tuberculosis, Household Contact
10/24
12/24
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
AUR1-8-341, NCT05515042: Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Active, not recruiting
2
694
RoW
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
The Aurum Institute NPC, Coalition for Epidemic Preparedness Innovations
COVID-19
06/24
12/24
NCT06205589: Therapeutic ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB

Not yet recruiting
2
1500
NA
ID93 + GLA-SE vaccine, Placebo vaccine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary
10/28
10/29
nTB-01, NCT06050356: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

Recruiting
1
140
RoW
H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose, H107e/CAF®10b - full adjuvant dose, Low dose intranasal H107e, Full dose intranasal H107e, H107e/CAF®10b, i.m. placebo, BCG, i.d. placebo, Intranasal H107e
Statens Serum Institut, Aurum Institute, Bill and Melinda Gates Foundation, Leiden University Medical Center, South African Tuberculosis Vaccine Initiative
Healthy
05/26
05/26
TBSEQUEL, NCT03251196: TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB

Active, not recruiting
N/A
1500
RoW
No Intervention, and Observational Study, Observational Study
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Research Center Borstel, University of Witwatersrand, South Africa, Mbeya Medical Research Centre NIMR, Ministry of Health Instituto Nacional de Saude, Medical Research Council Unit, The Gambia, Karolinska Institutet
Respiratory Tract Infections, Tuberculosis, Pulmonary
06/22
06/22
SMARTT, NCT05017324 / 2020-004084-10: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial

Recruiting
N/A
248
RoW
WGS DST strategy
Universiteit Antwerpen, Aurum Institute, University of Stellenbosch, University of the Free State, Free State Department of Health
Rifampicin Resistant Tuberculosis, Drug-resistant Tuberculosis, Multidrug Resistant Tuberculosis, Pulmonary Tuberculoses
12/22
01/25
Rassool, Mohammed Siddique
PRACTECAL-EE, NCT04207112: Economic Evaluation of New MDR TB Regimens

Completed
2/3
73
RoW
Bedaquiline, Sirturo, R207910, TMC207, Pretomanid, PA-824, Moxifloxacin, Avelox, BAY 12-8039, Linezolid, Zyvox, Clofazimine, Lamprene, Standard Drugs
Medecins Sans Frontieres, Netherlands, London School of Hygiene and Tropical Medicine, Ministry of Health, Republic of Uzbekistan, Ministry of Public Health, Republic of Belarus, THINK TB & HIV Investigative Network, University of Liverpool, Wits Health Consortium (Pty) Ltd
Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses
08/22
08/22
PRACTECAL-PRO, NCT03942354: Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Completed
2/3
137
RoW
Bedaquiline, Sirturo, R207910, TMC207, Pretomanid, PA-824, Moxifloxacin, Avelox, BAY 12-8039, Linezolid, Zyvox, Clofazimine, Lamprene, Directly observed therapy (DOT)
Medecins Sans Frontieres, Netherlands, University of Sussex, London School of Hygiene and Tropical Medicine, THINK TB & HIV Investigative Network, Wits Health Consortium (Pty) Ltd, Ministry of Public Health, Republic of Belarus, Ministry of Health, Republic of Uzbekistan
Multidrug Resistant Tuberculosis
05/22
05/22
panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting
2/3
352
RoW
Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development
Tuberculosis
09/25
09/25
NCT05221502: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Completed
2
122
RoW
Delamanid + Bedaquiline + OPC-167832 10 mg, Delamanid + Bedaquiline + OPC-167832 30 mg, Delamanid + Bedaquiline + OPC-167832 90 mg, RHEZ
Otsuka Pharmaceutical Development & Commercialization, Inc., Bill and Melinda Gates Foundation
Pulmonary TB
04/24
05/24
Sebe, Modulakgotla A
panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting
2/3
352
RoW
Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development
Tuberculosis
09/25
09/25
AUR1-8-341, NCT05515042: Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Active, not recruiting
2
694
RoW
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
The Aurum Institute NPC, Coalition for Epidemic Preparedness Innovations
COVID-19
06/24
12/24
NCT05221502: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Completed
2
122
RoW
Delamanid + Bedaquiline + OPC-167832 10 mg, Delamanid + Bedaquiline + OPC-167832 30 mg, Delamanid + Bedaquiline + OPC-167832 90 mg, RHEZ
Otsuka Pharmaceutical Development & Commercialization, Inc., Bill and Melinda Gates Foundation
Pulmonary TB
04/24
05/24
DOLPHIN Moms, NCT05122026: Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Recruiting
1/2
252
RoW
Rifapentine, Priftin, Isoniazid, Winthrop Isoniazid
The Aurum Institute NPC, Johns Hopkins University, Weill Medical College of Cornell University, University of Washington
HIV Seropositivity, Pregnancy, Tuberculosis Infection
12/24
03/25
Wallis, Robert S
NAC-TB, NCT03702738: Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis

Completed
2
110
RoW
N-acetyl cysteine, NAC
The Aurum Institute NPC, National Institute for Medical Research, Tanzania
Tuberculosis, Pulmonary
12/21
12/21
AUR1-1-199, NCT04930744: Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Recruiting
2
112
RoW
Isoniazid, Rifampicin, Ethambutol, Myambutol, Pyrazinamide, Metformin hydrochoride, Glucophage
University of Massachusetts, Worcester, National Institute of Allergy and Infectious Diseases (NIAID), Aurum Institute, A*STAR Infectious Diseases Labs, University of Cape Town, Wits Health Consortium (Pty) Ltd
Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection
11/25
11/25
Govender, Vaneshree
NCT05022212: Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition

Completed
2
45
RoW
LACTIN-V, Lactobacillus crispatus CTV-05, Placebo
University of California, San Francisco, University of KwaZulu, Harvard University, Aurum Institute, Health Systems Trust, Osel, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bacterial Vaginosis, HIV Infections
03/23
03/23
DOLPHIN Moms, NCT05122026: Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Recruiting
1/2
252
RoW
Rifapentine, Priftin, Isoniazid, Winthrop Isoniazid
The Aurum Institute NPC, Johns Hopkins University, Weill Medical College of Cornell University, University of Washington
HIV Seropositivity, Pregnancy, Tuberculosis Infection
12/24
03/25
DOLPHIN KIDS, NCT05122767: Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment

Recruiting
1/2
92
RoW
Dolutegravir, 3HP
The Aurum Institute NPC, Johns Hopkins University
Tuberculosis, HIV
12/24
12/25
nTB-01, NCT06050356: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

Recruiting
1
140
RoW
H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose, H107e/CAF®10b - full adjuvant dose, Low dose intranasal H107e, Full dose intranasal H107e, H107e/CAF®10b, i.m. placebo, BCG, i.d. placebo, Intranasal H107e
Statens Serum Institut, Aurum Institute, Bill and Melinda Gates Foundation, Leiden University Medical Center, South African Tuberculosis Vaccine Initiative
Healthy
05/26
05/26

Download Options